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Dengue Virus Type 2 Modulates Endothelial Barrier Function through CD73
Chinmay Patkar, Kris Giaya, and Daniel H. Libraty*
Division of Infectious Disease and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts
Abstract. Dengue hemorrhagic fever is characterized by a unique vascular leakage syndrome. The mechanisms of
endothelial barrier dysfunction in dengue hemorrhagic fever are not well understood. We examined the modulation of
endothelial barrier function in dengue virus type 2 (DENV2) infections using primary human umbilical vein endothelial
cells. We demonstrated that the increase in endothelial barrier function within 72 hours after DENV2 infection is mediated
by type I interferon–dependent CD73 up-regulation. After 72 hours, DENV2 slowed the recovery of endothelial barrier
function in response to tumor necrosis factor-a or vascular endothelial growth factor. This phenomenon was likely
caused by type I interferon receptor signaling inhibition and lower CD73 levels in DENV2-infected endothelial cells.
Our findings suggest that during DENV2 infection, endothelial barrier homeostasis is maintained by a balance between
pro-inflammatory and pro-angiogenic cytokines, and type I interferon–dependent CD73 expression and activity.
INTRODUCTION
Dengue is the most prevalent arthropod-borne viral illness
in humans, and half of the world’s population is at risk for
infection. There are up to 50 million cases of dengue esti-
mated each year resulting in 500,000 hospitalizations and
20,000 deaths.1 Dengue viruses (DENVs) are single-stranded,
positive-sense, RNA-containing enveloped viruses belonging
to the family Flaviviridae and the genus Flavivirus.2 There are
four serotypes of DENVs (DENV1–4).
Dengue virus infections produce a wide spectrum of clini-
cal illness. This spectrum ranges from asymptomatic or mild
illness to a severe and potentially life-threatening disease,
dengue hemorrhagic fever (DHF). The hallmark of DHF is
endothelial dysfunction. This dysfunction is manifested by a
vascular leakage syndrome and sometimes a hemorrhagic
diathesis. The morbidity and mortality of DHF are largely
driven by the vascular leakage and its ensuing complications.
The mechanisms of endothelial barrier dysfunction that
lead to the unique vascular leakage syndrome of DHF are
not well understood. Dengue viruses are not cytopathic to
endothelial cells in vitro.3,4 Viral antigen positive endothelial
cells have been seen in autopsy tissues with minimal or no
endothelial destruction.5,6 Vascular leakage develops abruptly
during viral clearance and early symptom recovery, at a time
of significant immune activation.7 The initial vascular leakage
is focal and occurs predominantly in the pleural and perito-
neal spaces.8 The prevailing explanation for DHF vascular
leakage is that immune responses to DENV infection produce
a cytokine storm that leads to the transient compromise of
endothelial barrier function.9 Many pro-inflammatory cyto-
kines (e.g., tumor necrosis factor-a [TNF-a]) and angiogene-
sis factors (e.g., vascular endothelial growth factor [VEGF])
can decrease endothelial barrier function and thereby increase
vascular permeability.10 This hyperpermeability is oftenmeasured
in vitro by transendothelial cell electrical resistance (TEER) of
monolayers.11,12 Circulating levels of many vascular permeabil-
ity mediators are increased in patients with DHF9 and can be
produced by DENV-infected cells in vitro.13,14
Most DENV-infected patients do not show development
of a vascular leakage syndrome. Several proteins and sig-
naling pathways are involved in maintenance of endothelial
barrier function, and one of these involves CD73 activity.
CD73 is a 5¢-ectonucleotidase and a glycophosphatidylinositol–
anchored protein that is expressed abundantly on endothelial
cells. The primary function of CD73 is to convert adenosine
monophosphate (5¢-AMP) to adenosine.15 Adenosine then
signals through endothelial adenosine 2b (A2b) receptors
and increases intracellular cyclic AMP levels that leads to
strengthened adherens junctions, and augments endothelial
barrier function.15,16
We had previously shown that DENV2 ameliorated TNF-
a–driven hyperpermeability of human umbilical vein endo-
thelial cell (HUVEC) monolayers at an early time point after
infection. This effect was mediated by type I interferon (IFN).
At a later time point, DENV2 infection augmented the TNF-
a–driven hyperpermeability of HUVEC monolayers.17 In this
report, we demonstrate that the increase in HUVEC barrier
function within 72 hours after DENV2 infection is mediated
by type I IFN-dependent CD73 up-regulation. After 72 hours,
DENV2 slowed the recovery of HUVEC barrier function in
response to TNF-a or VEGF treatment. Our data suggests
that this phenomenon was caused by the blockade of type I
IFN receptor (IFNAR) signaling and lower CD73 levels in
DENV2 containing endothelial cells.
METHODS
Reagents. Reagents used were recombinant (r)TNF-a
(Invitrogen, Carlsbad, CA), rIFN-b (PBL Laboratories,
Piscataway, NJ), rVEGF (Invitrogen), rB18R protein
(eBioscience, San Diego, CA), anti-IFNARmouse monoclonal
antibody (mAb) (PBL Laboratories), anti-CD73 mouse mAbs
(7G2; Invitrogen and 1E9; Santa Cruz Biotechnology, Santa
Cruz, CA), and mouse IgG1 isotype control (BD Pharmingen,
San Diego, CA). B18R is a soluble-type I IFN receptor analog
from vaccinia virus and is used to block type I IFN signaling.
Viruses and cells. Dengue virus type 2 strain NGC, origi-
nally obtained from the American Type Culture Collection
(Manassas, VA), was propagated in the mosquito cell line
C6/36. Virus stock titers were determined by limiting-dilution
plaque assay on Vero cells, and were free of endotoxin and
Mycoplasma contamination. Sendai virus (Cantell strain) at a
concentration of 4,000 hemagglutinin units/mL was obtained
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from Charles River (SPAFAS, Wilmington, MA). Primary
HUVECs were obtained from Lonza (Basel, Switzerland)
and cultured at 37°C in an atmosphere of 5% CO2 in endo-
thelial cell growth medium 2 supplemented with endothelial
cell growth medium 2–microvascular endothelial cell medium
2 SingleQuots (Lonza). All HUVEC experiments were per-
formed with subculture passage 2 cells.
DENV infection. The HUVECs were infected with DENV2
NGC at a multiplicity of infection of 5. Dengue virus type 2 was
adsorbed for 2 hours at 37°C, washed with phosphate-buffered
saline (Invitrogen), and fresh medium was added to the cells.
The HUVECs treated in a similar manner with C6/36 cell
supernatants instead of virus were used as uninfected controls.
Tranfection with small interfering RNA. Validated small
interfering RNAs for IFN-b promoter stimulator-1 (IPS-I, gene
accession no. NM_0207746), myeloid differentiation factor 88
(MyD88, gene accession no. NM_002468), and a non-silencing
control were obtained from QIAGEN (Valencia, CA). Trans-
fection of small interfering RNAs into HUVECs at a concen-
tration of 200 pmol for each sample was performed by using
the Amaxa™ electroporation system (Lonza), as per the man-
ufacturer’s instructions. Sendai virus was used as a positive
control for IPS-1–dependent IFN-b production. Targeted gene
knockdown was confirmed by using a quantitative reverse
transcription polymerase chain reaction (qRT-PCR).
Trans-endothelial electrical resistance assays. For measur-
ing TEER, HUVECs were plated at a concentration of 5 + 105
cells/well on collagen-coated transwell inserts (0.4-mm-pore,
6.5-mm-diameter, Transwell-COL, Costar; Corning, Ithaca, NY)
and incubated at 37°C in an atmosphere of 5% CO2. After
approximately two days, the HUVECs formed a confluent
monolayer. Dengue virus type 2, cytokines, or soluble media-
tors were added at the indicated concentrations and time points
to the top chamber. Electrical resistance across HUVEC
monolayers was measured by using an EndOhm-6 chamber
and EVOM volt-ohmmeter (World Precision Instruments,
Sarasota, FL), according to the manufacturer’s instructions.
Resistance measured by using a transwell insert with media
and no endothelial cells was considered a blank reading. TEER
was calculated as follows: TEER (W.cm2) = (sample-well
resistance – blank-well resistance) + area of cell monolayer.
Flow cytometry. For flow cytometry surface staining of
CD73, HUVECs were dissociated from the plate by treatment
with mild trypsin-EDTA (Lonza), resuspended in medium, and
incubated at 37°C in an atmosphere of 5% CO2 for 1 hour.
After two washes, anti-CD73 mouse mAb conjugated to
allophycocyanin (BD Biosciences, Franklin Lakes, NJ) was
added a concentration of at 50 ng per sample for 30 minutes at
4°C. Cells were then washed, fixed (Cytofix; BD Biosciences),
and analyzed by flow cytometry (FACSCalibur; BD
Immunocytometry Systems, San Jose, CA). For detection of
DENV infection, HUVECs were fixed and permeabilized by
using Cytofix/Cytoperm (BD Biosciences), stained with anti-
DENV prM 2H2 mouse mAb conjugated to Alexafluor 488
for 30 minutes at 4°C, washed (Perm/Wash buffer; BD Bio-
sciences), and analyzed by flow cytometry. Flow cytometry
data were analyzed using FlowJo™ version 6 (TreeStar, Inc.,
Ashland, OR).
Quantitative reverse transcription polymerase chain reaction.
Total RNA from HUVECs was extracted by using the
RNeasy Mini kit (QIAGEN) following the manufacturer’s
instructions. The qRT-PCR was performed by using the ABI
Prism 7300 sequence detection system (Applied Biosystems,
Foster City, CA) per the manufacturer’s instructions. Primer-
probe sets for human IFN-b (Hs00277188_s1), human CD73
(Hs01573922_m1), human A2b receptor (Hs00386497_m1),
and human glyceraldehyde 3-phosphate dehydrogenase
(Hs02758991_g1) were obtained from Applied Biosystems,
and qRT-PCR was performed using TaqMan One-step RT-
PCR kit (Applied Biosystems). Primers for human Robo4,
Tie-2, and Notch1-4 were obtained from Integrated DNA
Technologies (Coralville, IA), and qRT-PCR was performed
by using the SYBR Green qRT-PCR kit (Invitrogen). The
relative mRNA expression level of each gene was normalized
to the housekeeping gene glyceraldehyde 3-phosphate dehy-
drogenase, and relative gene expression levels were then
analyzed by using the 2−DDCt method.
Statistical analysis.Graphpad Prism version 5.0 (Graphpad,
San Diego, CA) was used for statistical analysis. For nor-
mally distributed variables, comparisons between two groups
were performed by using the parametric Student’s t test. For
non-normally distributed variables, comparisons between
Figure 1. Induction of interferon-b (IFN-b) production in human umbilical vein endothelial cells (HUVECs) through an IFN-b promoter
stimulator-1 (IPS-1)–dependent mechanism by dengue virus type 2 (DENV2). The HUVECs were transfected with the indicated small interfering
RNAs (siRNAs) by electroporation, and 24 h later were stimulated with DENV2 (multiplicity of infection [MOI] = 5) or Sendai virus (SeV, MOI =
0.03 by hemagglutinin units). Total cytoplasmic RNA was extracted from HUVECs and the relative expression of IFN-b mRNA was measured at
48 h by quantitative reverse transcription–polymerase chain reaction. Black bars =DENV2 stimulation; empty bars = SeV stimulation. Values and
error bars are mean ± SEM, n = 3 independent experiments. *P = 0.01 compared with no siRNA control.
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two groups were performed by using the non-parametric
Mann-Whitney U test. Comparisons among normally distrib-
uted multiple groups were performed using one-way or two-
way analysis of variance.
RESULTS
Induction of HUVEC IFN-b production by DENV2 in an
IPS-1–dependent manner. Dengue virus has been reported to
induce IFN-b production in cultured fibroblasts using the cyto-
plasmic RNA-sensing pattern recognition receptors retinoic
acid-inducible gene I and melanoma differentiation associated
protein 5.18 Retinoic acid-inducible gene I and melanoma
differentiation associated protein 5 use the downstream sig-
naling adaptor IPS-1 to stimulate IFN-b production. We
examined the role of IPS-1 signaling in DENV2 stimulation
of HUVEC IFN-b production. The DENV2 stimulation of
HUVEC IFN-b production was nearly completely dependent
on IPS-1 signaling, and not on MyD88 signaling (Figure 1).
Induction of up-regulation of CD73 expression in HUVECs
by DENV2 in a type I IFN-dependent manner.We had previ-
ously shown that type I IFN and DENV2 infection (early time
point) increase the barrier function of HUVEC monolayers.17
We measured the DENV2-infected HUVEC mRNA levels of
genes reported to be involved in the regulation of endothelial
barrier function (Robo4, Tie-2, Notch1-4, and CD73). Over the
first 72 hours after DENV2 infection, we found that HUVEC
CD73 mRNA and protein expression were up-regulated
(Figure 2A and B). None of the other genes tested were
up-regulated or down-regulated significantly by DENV2
infection in HUVECs. We also found that rIFN-b increased
CD73 expression in HUVECs, and DENV2-stimulated
HUVEC CD73 up-regulation was dependent on IFNAR sig-
naling (Figure 2). Our data demonstrate that DENV2 induces
type I IFN production in HUVECs and IFNAR signaling
leads to the up-regulation of CD73 in these cells.
Mediation by CD73 of DENV2-stimulated increase in barrier
function and amelioration of TNF-a–driven hyperpermeability
in HUVECs. At an early time point after infection, we had
previously shown that DENV2 infection of HUVECs amelio-
rated TNF-a–driven hyperpermeability, and this effect was
dependent on type I IFN production and signaling.17 To
Figure 2. Up-regulation of CD73 mRNA and surface protein expression in human umbilical vein endothelial cells (HUVECs) in a type I
interferon (IFN)–dependent manner by dengue virus type 2 (DENV2). For A and B, HUVECs were stimulated with recombinant (r) interferon-b
(IFN-b) (500 U/mL) or DENV2 (multiplicity of infection [MOI] = 5). A, Total cytoplasmic RNA was extracted from HUVECs and the relative
expression of CD73 mRNA was measured at the indicated time-points by quantitative reverse transcription polymerase chain reaction (qRT-
PCR). B, HUVECs were stained at 72 hours with anti-CD73 conjugated with allophycocyanin (APC), and the geometric mean fluorescence
intensity (gMFI) was measured by fluorescence-activated cell sorting (FACS). For C and D, HUVECs were pre-treated with either a combina-
tion of a blocking IFN-a receptor monoclonal antibody (IFNAR mAb) and rB18R or a control (ctrl) antibody (Ab) before stimulation with
rIFN-b (500 U/mL) or DENV2 (MOI = 5). C, Total cytoplasmic RNA was extracted from HUVECs and the relative expression of CD73 mRNA
was measured at 72 hours by qRT-PCR. D, HUVECs were stained at 72 hours with anti-CD73-APC Ab, and the gMFI was measured by FACS.
Shown are the gMFIs for samples pre-treated with blocking IFNAR mAb and rB18R. Dark gray bars = DENV2 stimulation; light gray bars =
rIFN-b stimulation; empty bars = uninfected cells. Values and error bars are mean ± SEM, n = 3 independent experiments. *P < 0.05, †P < 0.01
compared with uninfected control.
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investigate whether the amelioration of TNF-a–driven
hyperpermeability hyperpermeability in HUVECs was medi-
ated by CD73, we blocked CD73 activity and analyzed the
TEER of DENV2-infected HUVEC monolayers. The
HUVECs expressed A2b receptor mRNA. Therefore, CD73
activity could potentially increase barrier function. In accor-
dance with our previous report, we observed that TNF-a–
driven hyperpermeability was ameliorated at 72 hours in
HUVECs treated with rIFN-b or infected with DENV2.
When HUVECs were pre-treated with a blocking IFNAR
mAb and rB18R, or with a blocking anti-CD73 mAb (7G2),
TNF-a–driven hyperpermeability was no longer ameliorated
by DENV2 infection (Figure 3). Similar results were obtained
using a second anti-CD73 blocking mAb (1E9). Our data
demonstrate that the increase in HUVEC barrier function
within 72 hours after DENV2 infection is mediated by type I
IFN signaling and CD73.
Slowing of late recovery in barrier function of TNF-a– or
VEGF-treated HUVECs by DENV2 infection. The HUVEC
hyperpermeability induced by TNF-a, a pro-inflammatory
cytokine, or VEGF, a pro-angiogenic cytokine, is reversible.10
The HUVEC monolayers grown on collagen-coated transwell
membranes became permeable upon treatment with rTNF-a
or rVEGF. After day 3, TEER began to recover to near nor-
mal (untreated) levels in rTNF-a– or rVEGF–treated HUVEC
monolayers (Figure 4A). Dengue virus type 2 did not alter the
HUVEC TEER nadir produced by TNF-a or VEGF (when
Type I IFN receptor signaling was inhibited), but DENV2
infection slowed the TEER recovery (Figure 4B and C).
Lower CD73 expression in DENV2-infected HUVECs
than in uninfected bystander HUVECs. By day 3 after infec-
tion, approximately 20% of the HUVEC monolayer con-
tained DENV2 (multiplicity of infection = 5). The IFN-b
production in HUVECs continues to increase up to 5 days
after DENV2 infection.17 The DENV-infected cells produce
type I IFN but are known to cause potent inhibition of IFNAR
signaling.19,20 As such, we observed that CD73 surface protein
expression was lower in DENV2-infected HUVECs compared
with uninfected bystander HUVECs (Figure 4D), presumably
because of the inhibition of IFNAR signaling in these DENV2-
infected HUVECs. Expression of CD73 is higher in nearby
uninfected bystander HUVECs because type I IFN signaling
can occur unimpeded in these cells.
DISCUSSION
We have shown that DENV2 infection of HUVECs induces
type I IFN production in an IPS-1-dependent manner. Type I
IFN signaling up-regulates CD73 expression, and CD73 is
largely responsible for the DENV2 augmentation of HUVEC
monolayer barrier function. At later time points, DENV2
slows the recovery of barrier function in HUVEC monolayers
treated with TNF-a or VEGF. Our data suggests that the slow
recovery of barrier function is largely caused by impaired
IFNAR signaling and CD73 expression in endothelial cells
containing DENV2.
In essentially all DENV-infected patients, a vascular leak-
age syndrome is not seen over the first several days after
infection. Absence of this syndrome occurs despite a robust
innate immune response that produces pro-inflammatory
(e.g., TNF-a) and pro-angiogenic (e.g., VEGF) cytokines.9,21
We postulate that endothelial hyperpermeability driven by
pro-inflammatory and pro-angiogenic innate immune cyto-
kines is counteracted by DENV-induced type I IFN produc-
tion, signaling, and CD73 up-regulation in endothelial cells.
The DENV stimulated type I IFN production at early time
points may occur directly in endothelial cells, as shown here,
or in other non-endothelial cells.22,23 Activity of CD73
has been shown to enhance endothelial monolayer barrier
function through altered intracellular cyclic AMP levels,
TNF-α - + + + +
IFNAR Ab. + 
B18R - - + - -
Anti-CD73 
blocking Ab. - - - + -
Control Ab. - - - - +
Figure 3. Dengue virus type 2 (DENV2) amelioration of tumor necrosis factor-a (TNF-a)–driven hyperpermeability of human umbilical vein
endothelial cells (HUVECs) mediated by type I interferon (IFN) and CD73. HUVECs were grown to confluency in collagen-coated transwells and
in some cases pre-treated with a combination of a blocking interferon-a (IFN-a) receptor monoclonal antibody (IFNAR mAb) and rB18R, an
anti-CD73 blocking mAb (7G2), or a control Ab before stimulation with recombinant (r)IFN-b (500 U/mL) or DENV2 (multiplicity of infection
[MOI] = 5). HUVEC monolayers were then treated with rTNF-a (2 ng/mL), and the transendothelial electrical resistance (TEER) was measured
72 h later. Dark gray bars = DENV2 stimulation; light gray bars = rIFN-b stimulation; empty bars = uninfected cells. Values and error bars are
mean ± SEM, n = 3 independent experiments. *P < 0.05 compared with control HUVECs treated with rTNF-a.
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cell surface adhesion molecule expression, and actin cytoskel-
etal reorganization.16
A second heterologous DENV infection remains the most
significant relative risk factor for the development of DHF.24
However, the vascular leakage syndrome develops in only a few
persons with secondary DENV infections. We postulate that
host factors that promote pro-inflammatory or pro-angiogenic
cytokine production by cross-reactive adaptive immune
responses and inhibit type I IFN signaling and endothelial
CD73 activity would favor DHF development. Dengue virus
infection of endothelial cells in organ-specific vascular beds
increases with time. Dengue virus infection and several non-
structural proteins are potent inhibitors of IFNAR signal-
ing.19,20 This IFNAR signaling inhibition could lead to lower
Figure 4. Slowing of recovery of endothelial barrier function in human umbilical vein endothelial cells (HUVECs) treated with recombinant
tumor necrosis factor-a (rTNF-a) or vascular endothelial growth factor (rVEGF) by dengue virus type 2 (DENV2). HUVECs were grown to
confluency in collagen-coated transwells and pre-treated with a combination of a blocking interferon-a (IFN-a) receptor monoclonal antibody
(IFNAR mAb) and rB18R. A, HUVECs were treated with rTNF-a (2 ng/mL) or rVEGF (40 ng/mL) and the transendothelial electrical
resistance (TEER) was measured over the indicated time points. B, HUVECs were stimulated with DENV2 (multiplicity of infection [MOI] = 5)
and then treated with rTNF-a (2 ng/mL) or C, recombinant vascular endothelial growth factor (rVEGF) (40 ng/mL). TEER was measured at the
indicated time points. D, CD73 expression on the cell surface of DENV2-infected and DENV2-uninfected HUVECs was analyzed by flow
cytometry. The geometric mean fluorescence intensity (gMFI) for CD73 surface expression is shown. Values and error bars are mean ± SEM, n = 2
independent experiments.
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CD73 expression and activity in specific vascular beds, and
promote prolonged hyperpermeability in response to pro-
inflammatory or pro-angiogenic adaptive immune cytokines.
We used low-passaged primary HUVECs to develop a
mechanistic model of vascular leakage in DHF.25 The vascu-
lar endothelium within and among different organs is hetero-
geneous.26,27 However, the organ-specific endothelial tropism
of DENVs has not been well studied. The relatively undiffer-
entiated HUVECs formed tight inter-endothelial junctions.
However, inter-endothelial junction regulation may differ
among heterogeneous organ-specific endothelia and is a
potential limitation of our study. We also established a domi-
nant role for type I IFN-dependent CD73 expression in the
DENV2-induced regulation of endothelial barrier function.
Our findings do not exclude other mechanisms participating
in DENV modulation of endothelial barrier function.
In conclusion, our findings suggest that during DENV infec-
tions endothelial barrier homeostasis is maintained by a dynamic
balance between pro-inflammatory/pro-angiogenic cytokines,
and type I IFN-dependent CD73 expression and activity. Addi-
tional studies of this model using tissue-specific endothelial
cells isolated from pleura and peritoneum are planned.
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